Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
I
116TH CONGRESS
2D SESSION
H. R. 7104
To direct the Secretary of Health and Human Services to award contracts,
grants, and cooperative agreements to expand and enhance manufac-
turing capacity of vaccines and vaccine candidates to prevent the spread
of SARS–CoV–2 and COVID–19.
IN THE HOUSE OF REPRESENTATIVES
JUNE 4, 2020
Ms. KUSTER of New Hampshire (for herself and Mr. JEFFRIES) introduced
the following bill; which was referred to the Committee on Energy and
Commerce
A BILL
To direct the Secretary of Health and Human Services to
award contracts, grants, and cooperative agreements to
expand and enhance manufacturing capacity of vaccines
and vaccine candidates to prevent the spread of SARS–
CoV–2 and COVID–19.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
SECTION 1. VACCINE MANUFACTURING AND ADMINISTRA-
3
TION CAPACITY.
4
(a) ENHANCING MANUFACTURING CAPACITY.—
5
(1) IN GENERAL.—The Secretary of Health and
6
Human Services (in this section referred to as the
7
VerDate Sep 11 2014
02:29 Jun 27, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
2
•HR 7104 IH
‘‘Secretary’’) acting through the Director of the Bio-
1
medical Advanced Research and Development Au-
2
thority shall, as appropriate, award contracts,
3
grants, and cooperative agreements, and enter into
4
other transactions, to expand and enhance manufac-
5
turing capacity of vaccines and vaccine candidates to
6
prevent the spread of SARS–CoV–2 and COVID–19.
7
(2) AUTHORIZATION OF APPROPRIATIONS.—To
8
carry out this subsection, there are authorized to be
9
appropriated such sums as may be necessary for fis-
10
cal years 2020 through 2024, to remain available
11
until expended.
12
(b) REPORT ON VACCINE MANUFACTURING AND AD-
13
MINISTRATION CAPACITY.—
14
(1) IN GENERAL.—Not later than December 31,
15
2020, the Secretary shall submit to the Committee
16
on Energy and Commerce of the House of Rep-
17
resentatives and the Committee on Health, Edu-
18
cation, Labor and Pensions of the Senate a report
19
detailing—
20
(A) an assessment of the estimated supply
21
of vaccines and ancillary medical products re-
22
lated to vaccine administration necessary to
23
control and stop the spread of SARS–CoV–2
24
VerDate Sep 11 2014
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
3
•HR 7104 IH
and COVID–19, domestically and internation-
1
ally;
2
(B) an assessment of current and future
3
domestic manufacturing capacity for vaccines or
4
vaccine candidates to control or stop the spread
5
of SARS–CoV–2 and COVID–19, vaccine can-
6
didates, and ancillary products related to the
7
administration of such vaccines, including iden-
8
tification of any gaps in manufacturing capac-
9
ity;
10
(C) activities conducted to expand and en-
11
hance manufacturing capacity for vaccines, vac-
12
cine candidates, and ancillary medical products
13
to levels sufficient to control and stop the
14
spread of SARS–CoV–2 and COVID–19, do-
15
mestically and internationally, including a list
16
and explanation of all contracts, grants, and co-
17
operative agreements awarded, and other trans-
18
actions entered into, for purposes of such ex-
19
pansion and enhancement and how such activi-
20
ties will help to meet future domestic manufac-
21
turing capacity needs;
22
(D) a plan for the ongoing support of en-
23
hanced manufacturing capacity for vaccines,
24
vaccine candidates, and ancillary medical prod-
25
VerDate Sep 11 2014
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
4
•HR 7104 IH
ucts sufficient to control and stop the spread of
1
SARS–CoV–2 and COVID–19, domestically
2
and internationally; and
3
(E) a plan to support the administration of
4
vaccines approved or authorized by the Food
5
and Drug Administration to control and stop
6
the spread of SARS–CoV–2 and COVID–19,
7
domestically and internationally, including Fed-
8
eral workforce enhancements necessary to ad-
9
minister such vaccines.
10
(2) ANCILLARY MEDICAL PRODUCTS.—For pur-
11
poses of this subsection, ‘‘ancillary medical prod-
12
ucts’’ includes—
13
(A) vials;
14
(B) bandages;
15
(C) alcohol swabs;
16
(D) syringes;
17
(E) needles;
18
(F) gloves and other personal protective
19
equipment; and
20
(G) other medical products the Secretary
21
determines necessary for the administration of
22
vaccines.
23
Æ
VerDate Sep 11 2014
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS